Clinical factors associated with biochemical recurrence of prostate cancer with seminal vesicle invasion followed by robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).
Positive surgical margin
Prostate cancer
Robot-assisted radical prostatectomy
Seminal vesicle invasion
Journal
Journal of robotic surgery
ISSN: 1863-2491
Titre abrégé: J Robot Surg
Pays: England
ID NLM: 101300401
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
08
02
2023
accepted:
05
03
2023
medline:
28
7
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Locally advanced prostate cancer (PCa) with pathological seminal vesicle invasion (pT3b) is a very-high-risk disease associated with biochemical recurrence (BCR), local recurrence, distant metastases, or mortality following definitive therapies. This study aimed to evaluate the risk factors associated with BCR following robot-assisted radical prostatectomy (RARP) in PCa patients with pT3b. A retrospective multicenter cohort study was conducted on 3,195 patients with PCa who underwent RARP at nine domestic centers between September 2011 and August 2021. Biochemical recurrence-free survival (BRFS) after RARP in PCa patients with pT3b was the primary end-point of the study. The secondary end-point was to determine the association between BCR and covariates. We enrolled 188 PCa patients with pT3b. The median follow-up period was 32.8 months. At the end of the follow-up period, 76 patients (40.4%) developed BCR, of whom 15 (8.0%) were BCR at the date of surgery. The 1-, 2-, and 3-year BRFS rates were 76.4, 65.9, and 50.8%, respectively. Multivariate analysis identified initial prostate-specific antigen level and positive surgical margins (PSM) as significant predictors of BCR in PCa patients with pT3b undergoing RARP. In this study, we investigated the BRFS in PCa patients with pT3b. As PSM was an independent predictor of BCR in PCa patients with pT3b, these patients may require a combination of therapies to improve the BCR.
Identifiants
pubmed: 36928750
doi: 10.1007/s11701-023-01567-1
pii: 10.1007/s11701-023-01567-1
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1609-1617Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.
Références
Buyyounouski MK, Choyke PL, McKenney JK, et al (2017) Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:245–253. https://doi.org/10.3322/caac.21391
Mottet N, van den Bergh RCN, Briers E et al (2020) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243–262. https://doi.org/10.1016/j.eururo.2020.09.042
doi: 10.1016/j.eururo.2020.09.042
pubmed: 33172724
Poelaert F, Joniau S, Roumeguère T et al (2019) Current management of pT3b prostate cancer after robot-assisted laparoscopic prostatectomy. Eur Urol Oncol 2:110–117. https://doi.org/10.1016/j.euo.2018.05.005
doi: 10.1016/j.euo.2018.05.005
pubmed: 30929840
Prostate cancer [NCCN guidelines] ® 2022 (July 2021). Accessed Apr 4
Ilic D, Evans SM, Allan CA et al (2018) Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a cochrane systematic review. BJU Int 121:845–853. https://doi.org/10.1016/j.euo.2018.05.005
doi: 10.1016/j.euo.2018.05.005
pubmed: 29063728
Saika T, Miura N, Fukumoto T, Yanagihara Y, Miyauchi Y, Kikugawa T (2018) Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. Int J Urol 25:30–35. https://doi.org/10.1111/iju.13441
doi: 10.1111/iju.13441
pubmed: 28901630
Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee (2015) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228–1242 https://doi.org/10.1097/01.pas.0000173646.99337.b1 .
Pessoa RR, Maroni P, Kukreja J, Kim SP (2021) Comparative effectiveness of robotic and open radical prostatectomy. Transl Androl Urol 10:2158–2170. https://doi.org/10.21037/tau.2019.12.01
doi: 10.21037/tau.2019.12.01
pubmed: 34159098
pmcid: 8185666
Yossepowitch O, Bjartell A, Eastham JA et al (2009) Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 55:87–99. https://doi.org/10.1016/j.eururo.2008.09.051
doi: 10.1016/j.eururo.2008.09.051
pubmed: 18838211
Morizane S, Yumioka T, Makishima K et al (2021) Impact of positive surgical margin status in predicting early biochemical recurrence after robot-assisted radical prostatectomy. Int J Clin Oncol 26:1961–1967. https://doi.org/10.1007/s10147-021-01977-x
doi: 10.1007/s10147-021-01977-x
pubmed: 34313905
Fujimura T, Fukuhara H, Taguchi S et al (2017) Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy. BMC Cancer 17:454. https://doi.org/10.1186/s12885-017-3439-6
doi: 10.1186/s12885-017-3439-6
pubmed: 28662644
pmcid: 5492400
Fujita N, Koie T, Hashimoto Y et al (2018) Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution. Int Urol Nephrol 50:1999–2005. https://doi.org/10.1007/s11255-018-1985-8
doi: 10.1007/s11255-018-1985-8
pubmed: 30229466
Chierigo F, Wenzel M, Würnschimmel C et al (2022) Survival after radical prostatectomy versus radiation therapy in high-risk and very high-risk prostate cancer. J Urol 207:375–384. https://doi.org/10.1097/JU.0000000000002250
doi: 10.1097/JU.0000000000002250
pubmed: 34555930
Swanson GP, Goldman B, Tangen CM et al (2008) The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from southwest oncology group 8794. J Urol 180:2453–2457. https://doi.org/10.1016/j.juro.2008.08.037
doi: 10.1016/j.juro.2008.08.037
pubmed: 18930488
pmcid: 3512115
Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027. https://doi.org/10.1016/S0140-6736(12)61253-7
doi: 10.1016/S0140-6736(12)61253-7
pubmed: 23084481
Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol 27:2924–2930. https://doi.org/10.1200/JCO.2008.18.9563
doi: 10.1200/JCO.2008.18.9563
pubmed: 19433689
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649–655
doi: 10.1097/00000421-198212000-00014
pubmed: 7165009
Clark T, Parekh DJ, Cookson MS et al (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145–147. https://doi.org/10.1097/01.ju.0000039647.16278.17
doi: 10.1097/01.ju.0000039647.16278.17
pubmed: 12478123
Takagi K, Kawase M, Kato D et al (2022) Robot-assisted radical prostatectomy for potential cancer control in patients with metastatic prostate cancer. Curr Oncol 29:2864–2870. https://doi.org/10.3390/curroncol29040233
doi: 10.3390/curroncol29040233
pubmed: 35448207
pmcid: 9032850
Gandaglia G, De Lorenzis E, Novara G et al (2017) Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally advanced prostate cancer. Eur Urol 71:249–256. https://doi.org/10.1016/j.eururo.2016.05.008
doi: 10.1016/j.eururo.2016.05.008
pubmed: 27209538
Inoue T, Kinoshita H, Terada N et al (2015) Evaluation of prognostic factors after radical prostatectomy in pT3b prostate cancer patients in Japanese population. Jpn J Clin Oncol 45:780–784. https://doi.org/10.1093/jjco/hyv077
doi: 10.1093/jjco/hyv077
pubmed: 25981623
Lee HJ, Han JH, Lee DH et al (2016) Does bilateral seminal vesicle invasion at radical prostatectomy predict worse prognosis than unilateral invasion among patients with pT3b prostate cancers? Int J Urol 23:758–763. https://doi.org/10.1111/iju.13144
doi: 10.1111/iju.13144
pubmed: 27305865
Kim JK, Lee HJ, Hwang SI, Choe G, Hong SK (2020) Prognostic value of seminal vesicle invasion on preoperative multiparametric magnetic resonance imaging in pathological stage T3b prostate cancer. Sci Rep 10:5693. https://doi.org/10.1038/s41598-020-62808-z
doi: 10.1038/s41598-020-62808-z
pubmed: 32231265
pmcid: 7105461
Suh J, Jeong IG, Jeon HG et al (2020) Long-term oncologic outcomes of robot-assisted versus open radical prostatectomy for prostate cancer with seminal vesicle invasion: a multi-institutional study with a minimum 5-year follow-up. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-022-04243-3
doi: 10.1007/s00432-022-04243-3
pubmed: 32358699
Ceylan C, Tonyali S, Keles I (2016) Impact of positive surgical margin on biochemical recurrence following radical prostatectomy in locally advanced prostate cancer. Kaohsiung J Med Sci 32:514–517. https://doi.org/10.1016/j.kjms.2016.08.007
doi: 10.1016/j.kjms.2016.08.007
pubmed: 27742035
Ito K, Nakashima J, Mukai M et al (2003) Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol Int 70:297–302. https://doi.org/10.1159/000070139
doi: 10.1159/000070139
pubmed: 12740495
Van den Ouden D, Kranse R, Hop WC, Van der Kwast TH, Schroder FH (1998) Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol Int 60:17–24. https://doi.org/10.1159/000030197
doi: 10.1159/000030197
pubmed: 9519416
Hashimoto T, Nakashima J, Inoue R et al (2020) The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy. Int J Clin Oncol 25:377–383. https://doi.org/10.1007/s10147-019-01561-4
doi: 10.1007/s10147-019-01561-4
pubmed: 31673831
Numbere N, Teramoto Y, Gurung PMS, Goto T, Yang Z, Miyamoto H (2022) The clinical impact of pT3a lesions in patients with pT3bProstate cancer undergoing radical prostatectomy. Arch Pathol Lab Med 146:619–625. https://doi.org/10.5858/arpa.2021-0069-OA
doi: 10.5858/arpa.2021-0069-OA
pubmed: 34979562
Mazzone E, Gandaglia G, Stabile A et al (2022) Not all adverse pathology features are equal: identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy. J Urol 208:1046–1055. https://doi.org/10.1097/JU.0000000000002855
doi: 10.1097/JU.0000000000002855
pubmed: 35830554
Shaikh MP, Alite F, Wu MJ, Solanki AA, Harkenrider MM (2018) Adjuvant radiotherapy versus wait-and-see strategy for pathologic T3 or margin-positive prostate cancer: a meta-analysis. Am J Clin Oncol 41:730–738. https://doi.org/10.1097/COC.0000000000000358
doi: 10.1097/COC.0000000000000358
pubmed: 28225445
Tsurumaki Sato Y, Fukuhara H, Suzuki M et al (2014) Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol 14:13. https://doi.org/10.1186/1471-2490-14-13
doi: 10.1186/1471-2490-14-13
pubmed: 24476554
Vale CL, Fisher D, Kneebone A et al (2020) Adjuvant or early salvage radiotherapy for the treatment of localized and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 396:1422–1431. https://doi.org/10.1016/S0140-6736(20)31952-8
doi: 10.1016/S0140-6736(20)31952-8
pubmed: 33002431
pmcid: 7611137
Gandaglia G, Sun M, Trinh QD et al (2014) Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. BJU Int 114:E62–E69. https://doi.org/10.1111/bju.12645
doi: 10.1111/bju.12645
pubmed: 24467651
Koie T, Mitsuzuka K, Yoneyama T et al (2015) Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. Int J Clin Oncol 20:1018–1025. https://doi.org/10.1007/s10147-015-0802-y
doi: 10.1007/s10147-015-0802-y
pubmed: 25681879
Fujita N, Koie T, Ohyama C et al (2017) Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. Int J Clin Oncol 22:1087–1093. https://doi.org/10.1007/s10147-017-1160-8
doi: 10.1007/s10147-017-1160-8
pubmed: 28681153
Ghadjar P, Hayoz S, Genitsch V et al (2017) Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. BJU Int 120:E45–E51. https://doi.org/10.1111/bju.13742
doi: 10.1111/bju.13742
pubmed: 27987524